Sortina Pharma
Developing world-class small molecule therapeutics targeting sortilin, addressing life-threatening diseases.
Sortilin overexpression or dysfunction has been linked to certain diseases, such as cancer and neurodegenerative disorders, with great potential as a therapeutic target for various medical conditions.
Executive summary
Mission
Sortina's mission is to develop life-saving small molecule therapeutics targeting sortilin, focusing on critical diseases like cancer and neurodegenerative conditions.
Unique target and treatment strategy
Sortilin, a key player in cancer progression, will be targeted using an oral small molecule, revolutionizing cancer treatments, starting with Glioblastoma Multiforme.
Business plan
Develop optimal small molecules targeting Sortilin, creating a platform pipeline covering cancer and CNS indications and beyond. Seek partnerships at any time during development.
How to solve the cancer problem?
Novel cancer drug principle to target and eliminate treatment resistant cancer stem cells, preventing spread and enhancing conventional therapy efficiency.
Exit Strategy
Partnership agreements for our oncology program, CNS indications and beyond. Transformative therapies with multi-billion-dollar deal potential.
Investment opportunity
Sortina Pharma is actively seeking investment and collaborations to accelerate the development of our groundbreaking anti-sortilin small molecules for life-threatening diseases.
Competitive advantage
Strong IP covering chemical structures, first-in-class cancer treatment, oral administration, biomarkers, cost-effective manufacturing. Scalable technology for various cancers and CNS indications.
Team
Highly experienced team with expertise in various drug development areas. Spin-out from the University of Gothenburg, collaborating with academia and hospitals.
Join us in revolutionizing oncology treatment and beyond
Actively seeking investment- and collaborative partners for our development of groundbreaking anti-sortilin molecules, positioned for Glioblastoma Multiforme and additional sortilin-driving cancers.
Partnership opportunities for neurodegenerative diseases, and beyond.
Join us in extending therapeutic impact across diverse healthcare areas. Your support shapes the future of medical care.
Sara Rhost
Co-Founder, CEO
Partners and collaborators
News
